APO Research
Talk to an analyst

APO RESEARCH · REPORT

Targeting Small Molecule Tumor Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Targeting Small Molecule Tumor Drugs Market Outlook and Growth Opportunities 2026

2 January 2026203 pages

Choose your research edition.

Industry ResearchTargeting Small Molecule Tumor Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Targeting Small Molecule Tumor Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Targeting Small Molecule Tumor Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Targeting Small Molecule Tumor Drugs Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Targeting Small Molecule Tumor Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Targeting Small Molecule Tumor Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Targeting Small Molecule Tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Targeting Small Molecule Tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Targeting Small Molecule Tumor Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Targeting Small Molecule Tumor Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Targeting Small Molecule Tumor Drugs market include Yao Pharma, CHIATAI Tianqing, Zelgen, Simcere, Eisai, CSPC, Novartis, Roche and Jiangxi Shanxiang, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Targeting Small Molecule Tumor Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Targeting Small Molecule Tumor Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Targeting Small Molecule Tumor Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Targeting Small Molecule Tumor Drugs market.

Targeting Small Molecule Tumor Drugs Segment by Company

Yao Pharma

CHIATAI Tianqing

Zelgen

Simcere

Eisai

CSPC

Novartis

Roche

Jiangxi Shanxiang

Pfizer

BEACON Pharma

Bayer

AstraZeneca

Natco Pharma

Cipla

Bristol-Myers Squibb

Targeting Small Molecule Tumor Drugs Segment by Type

Alectinib

Anlotinib

Osimertinib

Lenvatinib

Regorafenib

Sorafenib

Other

Targeting Small Molecule Tumor Drugs Segment by Application

Hospital

Clinic

Other

Targeting Small Molecule Tumor Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Targeting Small Molecule Tumor Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Targeting Small Molecule Tumor Drugs key companies, revenue, market share, and recent developments.

3. To split the Targeting Small Molecule Tumor Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Targeting Small Molecule Tumor Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Targeting Small Molecule Tumor Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Targeting Small Molecule Tumor Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeting Small Molecule Tumor Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Targeting Small Molecule Tumor Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeting Small Molecule Tumor Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Targeting Small Molecule Tumor Drugs industry.

Chapter 3: Detailed analysis of Targeting Small Molecule Tumor Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Targeting Small Molecule Tumor Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Targeting Small Molecule Tumor Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Targeting Small Molecule Tumor Drugs Industry Trends Table 2. Targeting Small Molecule Tumor Drugs Industry Drivers Table 3. Targeting Small Molecule Tumor Drugs Industry Opportunities and Challenges Table 4. Targeting Small Molecule Tumor Drugs Industry Restraints Table 5. Global Targeting Small Molecule Tumor Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Targeting Small Molecule Tumor Drugs Revenue Share by Company (2021-2026) Table 7. Global Targeting Small Molecule Tumor Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Targeting Small Molecule Tumor Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Targeting Small Molecule Tumor Drugs Company, Product Type & Application Table 10. Global Targeting Small Molecule Tumor Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Targeting Small Molecule Tumor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Alectinib Table 15. Significant Companies of Anlotinib Table 16. Significant Companies of Osimertinib Table 17. Significant Companies of Lenvatinib Table 18. Significant Companies of Regorafenib Table 19. Significant Companies of Sorafenib Table 20. Significant Companies of Other Table 21. Global Targeting Small Molecule Tumor Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Targeting Small Molecule Tumor Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Targeting Small Molecule Tumor Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Type (2021-2026) Table 25. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Hospital Table 27. Significant Companies of Clinic Table 28. Significant Companies of Other Table 29. Global Targeting Small Molecule Tumor Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Targeting Small Molecule Tumor Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Targeting Small Molecule Tumor Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Application (2021-2026) Table 33. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Application (2027-2032) Table 34. Global Targeting Small Molecule Tumor Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Targeting Small Molecule Tumor Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Region (2021-2026) Table 37. Global Targeting Small Molecule Tumor Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Region (2027-2032) Table 39. Global Targeting Small Molecule Tumor Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Targeting Small Molecule Tumor Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Targeting Small Molecule Tumor Drugs Sales Value Market Share by Country (2021-2026) Table 42. Global Targeting Small Molecule Tumor Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Targeting Small Molecule Tumor Drugs Sales Value Market Share by Country (2027-2032) Table 44. Yao Pharma Company Information Table 45. Yao Pharma Business Overview Table 46. Yao Pharma Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Yao Pharma Targeting Small Molecule Tumor Drugs Product Portfolio Table 48. Yao Pharma Recent Development Table 49. CHIATAI Tianqing Company Information Table 50. CHIATAI Tianqing Business Overview Table 51. CHIATAI Tianqing Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. CHIATAI Tianqing Targeting Small Molecule Tumor Drugs Product Portfolio Table 53. CHIATAI Tianqing Recent Development Table 54. Zelgen Company Information Table 55. Zelgen Business Overview Table 56. Zelgen Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Zelgen Targeting Small Molecule Tumor Drugs Product Portfolio Table 58. Zelgen Recent Development Table 59. Simcere Company Information Table 60. Simcere Business Overview Table 61. Simcere Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Simcere Targeting Small Molecule Tumor Drugs Product Portfolio Table 63. Simcere Recent Development Table 64. Eisai Company Information Table 65. Eisai Business Overview Table 66. Eisai Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Eisai Targeting Small Molecule Tumor Drugs Product Portfolio Table 68. Eisai Recent Development Table 69. CSPC Company Information Table 70. CSPC Business Overview Table 71. CSPC Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. CSPC Targeting Small Molecule Tumor Drugs Product Portfolio Table 73. CSPC Recent Development Table 74. Novartis Company Information Table 75. Novartis Business Overview Table 76. Novartis Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis Targeting Small Molecule Tumor Drugs Product Portfolio Table 78. Novartis Recent Development Table 79. Roche Company Information Table 80. Roche Business Overview Table 81. Roche Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Roche Targeting Small Molecule Tumor Drugs Product Portfolio Table 83. Roche Recent Development Table 84. Jiangxi Shanxiang Company Information Table 85. Jiangxi Shanxiang Business Overview Table 86. Jiangxi Shanxiang Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Jiangxi Shanxiang Targeting Small Molecule Tumor Drugs Product Portfolio Table 88. Jiangxi Shanxiang Recent Development Table 89. Pfizer Company Information Table 90. Pfizer Business Overview Table 91. Pfizer Targeting Small Molecule Tumor Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Pfizer Targeting Small Molecule Tumor Drugs Product Portfolio Table 93. Pfizer Recent Development Table 94. BEACON Pharma Company Information Table 95. BEACON Pharma Business Overview Table 96. BEACON Pharma Targeting Small Molecule Tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. BEACON Pharma Targeting Small Molecule Tumor Drugs Product Portfolio Table 98. BEACON Pharma Recent Development Table 99. Bayer Company Information Table 100. Bayer Business Overview Table 101. Bayer Targeting Small Molecule Tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Bayer Targeting Small Molecule Tumor Drugs Product Portfolio Table 103. Bayer Recent Development Table 104. AstraZeneca Company Information Table 105. AstraZeneca Business Overview Table 106. AstraZeneca Targeting Small Molecule Tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. AstraZeneca Targeting Small Molecule Tumor Drugs Product Portfolio Table 108. AstraZeneca Recent Development Table 109. Natco Pharma Company Information Table 110. Natco Pharma Business Overview Table 111. Natco Pharma Targeting Small Molecule Tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Natco Pharma Targeting Small Molecule Tumor Drugs Product Portfolio Table 113. Natco Pharma Recent Development Table 114. Cipla Company Information Table 115. Cipla Business Overview Table 116. Cipla Targeting Small Molecule Tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Cipla Targeting Small Molecule Tumor Drugs Product Portfolio Table 118. Cipla Recent Development Table 119. Bristol-Myers Squibb Company Information Table 120. Bristol-Myers Squibb Business Overview Table 121. Bristol-Myers Squibb Targeting Small Molecule Tumor Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Bristol-Myers Squibb Targeting Small Molecule Tumor Drugs Product Portfolio Table 123. Bristol-Myers Squibb Recent Development Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Targeting Small Molecule Tumor Drugs Product Image Figure 2. Global Targeting Small Molecule Tumor Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Targeting Small Molecule Tumor Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Targeting Small Molecule Tumor Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Alectinib Image Figure 8. Anlotinib Image Figure 9. Osimertinib Image Figure 10. Lenvatinib Image Figure 11. Regorafenib Image Figure 12. Sorafenib Image Figure 13. Other Image Figure 14. Global Targeting Small Molecule Tumor Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Targeting Small Molecule Tumor Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Targeting Small Molecule Tumor Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Targeting Small Molecule Tumor Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Application (2021-2032) Figure 23. Global Targeting Small Molecule Tumor Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Targeting Small Molecule Tumor Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Targeting Small Molecule Tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. North America Targeting Small Molecule Tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Targeting Small Molecule Tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Targeting Small Molecule Tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Targeting Small Molecule Tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Targeting Small Molecule Tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Targeting Small Molecule Tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. South America Targeting Small Molecule Tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Targeting Small Molecule Tumor Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Targeting Small Molecule Tumor Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • Alectinib
  • Anlotinib
  • Osimertinib
  • Lenvatinib
  • Regorafenib
  • Sorafenib
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Yao Pharma
  • CHIATAI Tianqing
  • Zelgen
  • Simcere
  • Eisai
  • CSPC
  • Novartis
  • Roche
  • Jiangxi Shanxiang
  • Pfizer
  • BEACON Pharma
  • Bayer
  • AstraZeneca
  • Natco Pharma
  • Cipla
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Targeting Small Molecule Tumor Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Targeting Small Molecule Tumor Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Targeting Small Molecule Tumor Drugs Market Dynamics
  1. 2.1 Targeting Small Molecule Tumor Drugs Industry Trends
  2. 2.2 Targeting Small Molecule Tumor Drugs Industry Drivers
  3. 2.3 Targeting Small Molecule Tumor Drugs Industry Opportunities and Challenges
  4. 2.4 Targeting Small Molecule Tumor Drugs Industry Restraints
3 Targeting Small Molecule Tumor Drugs Market by Company
  1. 3.1 Global Targeting Small Molecule Tumor Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Targeting Small Molecule Tumor Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Targeting Small Molecule Tumor Drugs Company Ranking (2024-2026)
  4. 3.4 Global Targeting Small Molecule Tumor Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Targeting Small Molecule Tumor Drugs Company Product Type and Application
  6. 3.6 Global Targeting Small Molecule Tumor Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Targeting Small Molecule Tumor Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Targeting Small Molecule Tumor Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Targeting Small Molecule Tumor Drugs Market by Type
  1. 4.1 Targeting Small Molecule Tumor Drugs Type Introduction
  2. 4.1.1 Alectinib
  3. 4.1.2 Anlotinib
  4. 4.1.3 Osimertinib
  5. 4.1.4 Lenvatinib
  6. 4.1.5 Regorafenib
  7. 4.1.6 Sorafenib
  8. 4.1.7 Other
  9. 4.2 Global Targeting Small Molecule Tumor Drugs Sales Value by Type
  10. 4.2.1 Global Targeting Small Molecule Tumor Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Targeting Small Molecule Tumor Drugs Sales Value by Type (2021-2032)
  12. 4.2.3 Global Targeting Small Molecule Tumor Drugs Sales Value Share by Type (2021-2032)
5 Targeting Small Molecule Tumor Drugs Market by Application
  1. 5.1 Targeting Small Molecule Tumor Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Targeting Small Molecule Tumor Drugs Sales Value by Application
  6. 5.2.1 Global Targeting Small Molecule Tumor Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Targeting Small Molecule Tumor Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Targeting Small Molecule Tumor Drugs Sales Value Share by Application (2021-2032)
6 Targeting Small Molecule Tumor Drugs Regional Value Analysis
  1. 6.1 Global Targeting Small Molecule Tumor Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Targeting Small Molecule Tumor Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Targeting Small Molecule Tumor Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Targeting Small Molecule Tumor Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Targeting Small Molecule Tumor Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Targeting Small Molecule Tumor Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Targeting Small Molecule Tumor Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Targeting Small Molecule Tumor Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Targeting Small Molecule Tumor Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Targeting Small Molecule Tumor Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Targeting Small Molecule Tumor Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Targeting Small Molecule Tumor Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Targeting Small Molecule Tumor Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Targeting Small Molecule Tumor Drugs Sales Value Share by Country, 2025 VS 2032
7 Targeting Small Molecule Tumor Drugs Country-level Value Analysis
  1. 7.1 Global Targeting Small Molecule Tumor Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Targeting Small Molecule Tumor Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Targeting Small Molecule Tumor Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Targeting Small Molecule Tumor Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Targeting Small Molecule Tumor Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Targeting Small Molecule Tumor Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Targeting Small Molecule Tumor Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yao Pharma
  2. 8.1.1 Yao Pharma Company Information
  3. 8.1.2 Yao Pharma Business Overview
  4. 8.1.3 Yao Pharma Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yao Pharma Targeting Small Molecule Tumor Drugs Product Portfolio
  6. 8.1.5 Yao Pharma Recent Developments
  7. 8.2 CHIATAI Tianqing
  8. 8.2.1 CHIATAI Tianqing Company Information
  9. 8.2.2 CHIATAI Tianqing Business Overview
  10. 8.2.3 CHIATAI Tianqing Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 CHIATAI Tianqing Targeting Small Molecule Tumor Drugs Product Portfolio
  12. 8.2.5 CHIATAI Tianqing Recent Developments
  13. 8.3 Zelgen
  14. 8.3.1 Zelgen Company Information
  15. 8.3.2 Zelgen Business Overview
  16. 8.3.3 Zelgen Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zelgen Targeting Small Molecule Tumor Drugs Product Portfolio
  18. 8.3.5 Zelgen Recent Developments
  19. 8.4 Simcere
  20. 8.4.1 Simcere Company Information
  21. 8.4.2 Simcere Business Overview
  22. 8.4.3 Simcere Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Simcere Targeting Small Molecule Tumor Drugs Product Portfolio
  24. 8.4.5 Simcere Recent Developments
  25. 8.5 Eisai
  26. 8.5.1 Eisai Company Information
  27. 8.5.2 Eisai Business Overview
  28. 8.5.3 Eisai Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eisai Targeting Small Molecule Tumor Drugs Product Portfolio
  30. 8.5.5 Eisai Recent Developments
  31. 8.6 CSPC
  32. 8.6.1 CSPC Company Information
  33. 8.6.2 CSPC Business Overview
  34. 8.6.3 CSPC Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CSPC Targeting Small Molecule Tumor Drugs Product Portfolio
  36. 8.6.5 CSPC Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Targeting Small Molecule Tumor Drugs Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Roche
  44. 8.8.1 Roche Company Information
  45. 8.8.2 Roche Business Overview
  46. 8.8.3 Roche Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Roche Targeting Small Molecule Tumor Drugs Product Portfolio
  48. 8.8.5 Roche Recent Developments
  49. 8.9 Jiangxi Shanxiang
  50. 8.9.1 Jiangxi Shanxiang Company Information
  51. 8.9.2 Jiangxi Shanxiang Business Overview
  52. 8.9.3 Jiangxi Shanxiang Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangxi Shanxiang Targeting Small Molecule Tumor Drugs Product Portfolio
  54. 8.9.5 Jiangxi Shanxiang Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Targeting Small Molecule Tumor Drugs Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 BEACON Pharma
  62. 8.11.1 BEACON Pharma Company Information
  63. 8.11.2 BEACON Pharma Business Overview
  64. 8.11.3 BEACON Pharma Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 BEACON Pharma Targeting Small Molecule Tumor Drugs Product Portfolio
  66. 8.11.5 BEACON Pharma Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer Targeting Small Molecule Tumor Drugs Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Targeting Small Molecule Tumor Drugs Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 Natco Pharma
  80. 8.14.1 Natco Pharma Company Information
  81. 8.14.2 Natco Pharma Business Overview
  82. 8.14.3 Natco Pharma Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Natco Pharma Targeting Small Molecule Tumor Drugs Product Portfolio
  84. 8.14.5 Natco Pharma Recent Developments
  85. 8.15 Cipla
  86. 8.15.1 Cipla Company Information
  87. 8.15.2 Cipla Business Overview
  88. 8.15.3 Cipla Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Cipla Targeting Small Molecule Tumor Drugs Product Portfolio
  90. 8.15.5 Cipla Recent Developments
  91. 8.16 Bristol-Myers Squibb
  92. 8.16.1 Bristol-Myers Squibb Company Information
  93. 8.16.2 Bristol-Myers Squibb Business Overview
  94. 8.16.3 Bristol-Myers Squibb Targeting Small Molecule Tumor Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Bristol-Myers Squibb Targeting Small Molecule Tumor Drugs Product Portfolio
  96. 8.16.5 Bristol-Myers Squibb Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst